Name: Payables Turnover

Definition: Payables turnover shows how fast the company pays its suppliers for goods or services bought on credit. A high turnover means the company pays suppliers quickly, which may reflect strong cash flow or favorable terms. A very low turnover might mean the company is stretching payments to preserve cash — or possibly experiencing financial strain.

Interpretation:
• In '2021', BMRA's payables turnover was 15.85, indicating how promptly the company pays its suppliers. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at 4.18.
• In '2022', BMRA's payables turnover was 27.24, indicating how promptly the company pays its suppliers. The increase since '2021' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at 4.52. Industry average increased by 0.34 compared to previous year.
• In '2023', BMRA's payables turnover was 9.06, indicating how promptly the company pays its suppliers. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 4.33. Industry average declined by 0.19 from previous year.
• In '2024', BMRA's payables turnover was 15.20, indicating how promptly the company pays its suppliers. The increase since '2023' reflects strengthening financial performance. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 3.40. Industry average declined by 0.94 from previous year.
Overall, BMRA's payables turnover has been volatile but showed a downward trend over the past 4 years.

Formula: Payables Turnover = Cost of Goods Sold / Average Accounts Payable

Good Range: Ranges 5-15 depending on industry.